Present status of immunotherapy of hepatocellular carcinoma

  • Kiwamu Okita


Systemic treatment of hepatocellular carcinoma (HCC) with conventional chemotherapeutic agents in general seems to be very poor, as well as for other gastrointestinal malignancies. In this sense, transarterial embolization (TAE) [1], lipiodolization [2] and percutaneous ethanol injection (PEI) [3] have been expected to be more effective therapy, because those therapies can cause tumor necrosis by direct action. There is no doubt these modalities have brought prolonged the life expectency of HCC patients.


Percutaneous Ethanol Injection Natural Killer Activity Adoptive Immunotherapy Conventional Chemotherapeutic Agent Antigrowth Activity 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Yamada R, Sato M, Kawabata M, Nakatsuka H, Nakamura K, Takashima S (1983) Hepatic artery embolization in 120 patients with unresectable hepatoma. Radiology 148: 397–401PubMedGoogle Scholar
  2. 2.
    Kanematsu T, Inokuchi K, Sugimachi K, Furuta T, Sonoda T, Tamura S, Hasuno K (1984) Selective effects of lipiodolized antitumor agents. J Surg Oncol 25: 218–226PubMedCrossRefGoogle Scholar
  3. 3.
    Shinagawa T, Ukaji H, Iino Y, Isomura S, Yamaguchi H, Ishizuka M, Sugiura N, Ohto M (1985) Intratumoral injection of absolute ethanol under ultrasound imaging for treatment of small hepatocellular carcinoma. Attempts in three cases. Acta Hepatol Jpn 26: 99–105CrossRefGoogle Scholar
  4. 4.
    Hirofuji H, Kakumu S, Fuji A, Ohtani Y, Murase K, Tahara H (1987) Natural killer and activated killer activities in chronic liver diseases and hepatocellular carcinoma: Evidence for a decreased lymphokine-induced activity of effector cells. Clin Exp Immunol 68: 348–356PubMedGoogle Scholar
  5. 5.
    Saibara T, Ohnishi S, Sakaeda H, Yamamoto Y (1989) Defective function of lymphokine-activated killer cells and natural killer cells in patients with hepatocellular carcinoma. Hepatology 9: 471–476PubMedCrossRefGoogle Scholar
  6. 6.
    Sinkovics J (1978) Immunotherapy of human tumors. Pathobiol Ann 8: 241–273Google Scholar
  7. 7.
    Trinchieri G, Sourtoli D, Kopronski H (1978) Spontaneous cell mediated cytotoxicity in humans: Role of interferon and immunoglobulins. J Immunol 120: 1849–1855PubMedGoogle Scholar
  8. 8.
    Henry CS, Karibayashi K, Kern DE, Gillis S (1981) Interleukin-2 augments natural killer cytotoxicity. Nature 291: 335–338CrossRefGoogle Scholar
  9. 9.
    Grimm EA, Mazumder A, Zhang HZ, Rosenberg SA (1982) Lymphokine-activated killer cell phenomenon. Lysis of natural killer-resistant fresh solid tumor cells by interleukin-2-activated autologous human peripheral blood lymphocytes. J Exp Med 155: 1823–1841PubMedCrossRefGoogle Scholar
  10. 10.
    Dunk AA, Ikeda T, Pignatelli M, Thomas HC (1986) Human lymphoblastoid interferon: In vivo and in vitro studies in hepatocellular carcinoma. J Hepatol 2: 419–429PubMedCrossRefGoogle Scholar
  11. 11.
    Isaacs A, Lindermann J (1957) Virus interference. The interferon. Proc R Soc Lond [Biol] 147: 259–267Google Scholar
  12. 12.
    Sachs E, Di Bisceglie AM, Dusheiko GM, Song E, Lyons SF, Schoub BD, Kew MC (1985) Treatment of hepatocellular carcinoma with recombinant leukocyte interferon: A pilot study. Br J Cancer 52: 105–109PubMedCrossRefGoogle Scholar
  13. 13.
    Yoshida T, Okazaki N, Yoshino M, Ohkura H, Shimada Y (1990) Phase II trial of high dose recombinant gamma-interferon in advanced hepatocellular carcinoma. Eur J Cancer 26: 545–546PubMedGoogle Scholar
  14. 14.
    Forbes A, Johnson DJ, William R (1985) Recombinant human gamma-interferon in primary hepatocellular carcinoma. J R Soc Med 78: 826–829PubMedGoogle Scholar
  15. 15.
    Okita K, Kaneko T (1990) The potential of interferon in malignant disease. Drugs 39: 1–6PubMedCrossRefGoogle Scholar
  16. 16.
    Rosenstein N, Yron I, Kaufmann Y, Rosenberg SA (1984) Lymphokine-activated killer cell lysis of fresh syngenic natural killer-resistant murine tumor cells by lymphocytes cultured in interleukin-2. Cancer Res 44: 1946–1953PubMedGoogle Scholar
  17. 17.
    Rosenberg S, Lotze M, Muul L, Leitman S, Chang AE, Ettinghausen SE, Matory YL, Skibber JM, Shiloni E, Vetto JT, Seipp LA, Simpon C, Reichter LM (1985) Observations on the systemic administration of autologous lymphokine-activated killer cells and recombinant interleukin-2 to patients with metastatic cancer. N Engl J Med 313: 1485–1492PubMedCrossRefGoogle Scholar
  18. 18.
    Okuno K, Takagi H, Nakamura T, Nakamura Y, Iwase Z, Yasutomi M (1986) Treatment for unresectable hepatoma via selective hepatic artery infusion of lymphokine-activated killer cells generated from autologous spleen cells. Cancer 58: 1001–1006PubMedCrossRefGoogle Scholar
  19. 19.
    Ishikawa T, Imawari M, Moriyama T, Ohnishi S, Matsuhashi N, Suzuki G, Takaku F (1988) Immunotherapy of hepatocellular carcinoma with autologous lymphokine-activated killer cells and/or recombinant interleukin-2. J Cancer Res Clin Oncol 114: 283–290PubMedCrossRefGoogle Scholar
  20. 20.
    Ohnishi S, Saibara T, Fujikawa M, Sakaeda H, Matsuura Y, Matsunaga Y, Yamamoto Y (1989) Adoptive immunotherapy with lymphokineactivated killer cells plus recombinant interleukin-2 in patients with unresectable hepatocellular carcinoma. Hepatology 10: 349–353CrossRefGoogle Scholar
  21. 21.
    Gandolfi L, Solmi L, Pizza GC, Berfoni F, Muratoori R, De Vinci C, Bacchini P, Morelli MC, Corrado G (1989) Intratumoral echo-guided injection of interleukin-2 and lymphokine-activated killer cells in hepatocellular carcinoma. Hepatogastroenterology 36: 352–356PubMedGoogle Scholar
  22. 22.
    Livraghi T, Festi D, Monti F, Salmi A, Vettori C (1986) US-guided percutaneous alcohol injection of small hepatic and abdominal tumors. Radiology 16: 309–312Google Scholar
  23. 23.
    Sheu J-C, Huang G-T, Chen D-S, Sung J-L, Yang P-M, Lin T C-T, Chuang C-N (1987) Small hepatocellular carcinoma: Intratumor ethanol treatment using new needle and guidance systems. Radiology 163: 43–48PubMedGoogle Scholar
  24. 24.
    Ishida N (1986) Immunopotentiating activities of OK-432. In: Ishida N (ed) OK-432: Recent advances in the understanding of its mechanism of action. Excerpta Medica, Amsterdam, pp 41–84Google Scholar
  25. 25.
    Imaoka S, Sasaki Y, Ishikawa O, Ouhigashi H, Koyama H, Iwanaga T, Terasawa T (1986) Immunochemotherapy in human hepatocellular carcinoma using the streptococcal agent OK-432. J ClinOncol 4: 1645–1651PubMedGoogle Scholar
  26. 26.
    Huang G-T, Yang P-M, Sheu J-C, Hsu J-L, Sung J-L, Wang T-H, Chen D-C (1990) Intratumoral injection of OK-432 for the treatment of small hepatocellular carcinoma. Hepatogastroenterology 37: 452–456PubMedGoogle Scholar
  27. 27.
    Old LJ (1985) Tumor necrosis factor. Science 230: 0630–632CrossRefGoogle Scholar
  28. 28.
    Carswell EA, Old LJ, Kassel RL, Green S, Fiore N, Williamson B (1975) An endotoxin-induced serum factor that causes necrosis of tumors. Proc Natl Acad Sci USA 72: 3666–3670PubMedCrossRefGoogle Scholar
  29. 29.
    Liu Y-K, Yang K-Z, Wu Y-D, Gang Y-Q, Zhu D-N (1983) Treatment of advanced primary hepatocellular carcinoma by 131I-anti AFP. Lancet 1: 531–532PubMedCrossRefGoogle Scholar
  30. 30.
    Tang Z-Y, Liu K-D, Bao Y-M, Lu J-Z, Yu Y-Q, Chen Z-C, Zhou X-D, Yang R, Gan Y-H, Lin Z-Y, Fan Z, Hou Z (1990) Radioimmunotherapy in the multi-modality treatment of hepatocellular carcinoma with reference to second-look resection. Cancer 65: 211–215PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag Tokyo 1992

Authors and Affiliations

  • Kiwamu Okita
    • 1
  1. 1.First Department of Internal MedicineYamaguchi University School of MedicineUbe, YamaguchiJapan

Personalised recommendations